Masashi Mizokami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masashi Mizokami has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Etsuro Orito
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
10 shared publications Masahiko Yamamoto
4 shared publicationsTomoyoshi Ohno
3 shared publicationsFukunori Kinjo
First Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan
2 shared publicationsHiroki Nakasone
First Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan
2 shared publicationsKaoru Suzuki
2 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 98
P061 Association of HLA class II genes with response to hepatitis B vaccine in Japanese
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 98
P061 Association of HLA class II genes with response to hepatitis B vaccine in Japanese
- 27 January 2015
- Published by Wiley in Hepatology Research
- Vol. 45 (12) , 1220-1227
Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents
Aim The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients’ medical records. Methods Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late‐onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.
- 27 January 2015
- Published by Wiley in Hepatology Research
- Vol. 45 (12) , 1220-1227
Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents
Aim The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients’ medical records. Methods Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late‐onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.
- 1 May 2011
- p. 80-5
[Genome-wide association study and clinical application].
- 1 January 2005
- Published by Japan Society of Hepatology in Kanzo
- Vol. 46 (1) , 26-32
A case of autoimmune hepatitis superimposed by Ukon-induced liver injury
症例は50歳の女性. 黄疸を伴う急性肝炎にて入院し, 臨床経過, 肝組織検査, 診断基準より慢性肝障害に合併したウコンによる薬物性肝障害と診断した. ウコンの服用中止後も肝障害が遷延したためプレドニゾロンを使用. プレドニゾロンは奏効し肝障害改善後退院となった. 外来にてプレドニゾロンを中止したが, 中止後50日目に再び肝障害を認めたため2回目の入院となった. 肝組織検査, 診断基準に基づき検討したところ, 2回目の肝障害は自己免疫性肝炎であった. 1回目の肝障害と2回目の肝障害を再検討したが, ウコンによる薬物性肝障害がtriggerとなって自己免疫性肝炎が誘導された可能性と, もともと自己免疫性肝炎が存在しウコン内服によりなんらかの影響を受けて急性増悪した可能性が考えられた.
- 1 January 2005
- Published by Japan Society of Hepatology in Kanzo
- Vol. 46 (1) , 26-32
A case of autoimmune hepatitis superimposed by Ukon-induced liver injury
症例は50歳の女性. 黄疸を伴う急性肝炎にて入院し, 臨床経過, 肝組織検査, 診断基準より慢性肝障害に合併したウコンによる薬物性肝障害と診断した. ウコンの服用中止後も肝障害が遷延したためプレドニゾロンを使用. プレドニゾロンは奏効し肝障害改善後退院となった. 外来にてプレドニゾロンを中止したが, 中止後50日目に再び肝障害を認めたため2回目の入院となった. 肝組織検査, 診断基準に基づき検討したところ, 2回目の肝障害は自己免疫性肝炎であった. 1回目の肝障害と2回目の肝障害を再検討したが, ウコンによる薬物性肝障害がtriggerとなって自己免疫性肝炎が誘導された可能性と, もともと自己免疫性肝炎が存在しウコン内服によりなんらかの影響を受けて急性増悪した可能性が考えられた.
- 1 November 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (11) , 1305-1311
Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan
The aim of this study was to examine whether particular hepatitis C virus (HCV) subtypes are spreading among injecting drug users (IDUs) in Yamaguchi prefecture, on the south-western tip of the island of Honshu in Japan, as found in European countries. We prospectively enrolled acute hepatitis C patients from January 2001 to March 2003. E2 gene sequences of HCV isolates from IDUs with acute hepatitis C were phylogenetically compared to those from 30 chronic hepatitis C patients with the same HCV subtypes who had or did not have a history of intravenous drug use. Nine of 11 patients (82%) with acute hepatitis C were IDUs. The HCV subtypes were 2a in four and 2b in five, which contrasted with the high prevalence of subtype 1b in patients with chronic liver diseases in Japan. IDUs with acute hepatitis C (22.0 +/- 2.4 years old) were significantly younger than those with chronic hepatitis C (49.5 +/- 9.5 years old) for subtype 2a (P = 0.0005), but not for subtype 2b (25.6 +/- 5.4 vs 28.1 +/- 2.4 years old). Some HCV isolates of subtype 2b from IDUs with acute hepatitis C were phylogenetically related to those from IDUs with chronic hepatitis C. By contrast, there was no phylogenetic segregation of HCV in IDUs with subtype 2a. HCV isolates from non-IDUs were genetically divergent from each other and those from IDUs, irrespective of the HCV subtype. Hepatitis C virus of the non-1b subtype, particularly subtype 2b, seemed to be transmitted between IDUs very recently in Yamaguchi prefecture, Japan.
- 1 November 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (11) , 1305-1311
Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan
The aim of this study was to examine whether particular hepatitis C virus (HCV) subtypes are spreading among injecting drug users (IDUs) in Yamaguchi prefecture, on the south-western tip of the island of Honshu in Japan, as found in European countries. We prospectively enrolled acute hepatitis C patients from January 2001 to March 2003. E2 gene sequences of HCV isolates from IDUs with acute hepatitis C were phylogenetically compared to those from 30 chronic hepatitis C patients with the same HCV subtypes who had or did not have a history of intravenous drug use. Nine of 11 patients (82%) with acute hepatitis C were IDUs. The HCV subtypes were 2a in four and 2b in five, which contrasted with the high prevalence of subtype 1b in patients with chronic liver diseases in Japan. IDUs with acute hepatitis C (22.0 +/- 2.4 years old) were significantly younger than those with chronic hepatitis C (49.5 +/- 9.5 years old) for subtype 2a (P = 0.0005), but not for subtype 2b (25.6 +/- 5.4 vs 28.1 +/- 2.4 years old). Some HCV isolates of subtype 2b from IDUs with acute hepatitis C were phylogenetically related to those from IDUs with chronic hepatitis C. By contrast, there was no phylogenetic segregation of HCV in IDUs with subtype 2a. HCV isolates from non-IDUs were genetically divergent from each other and those from IDUs, irrespective of the HCV subtype. Hepatitis C virus of the non-1b subtype, particularly subtype 2b, seemed to be transmitted between IDUs very recently in Yamaguchi prefecture, Japan.
- 1 August 2004
- p. 233-7
[Hepatitis B virus genotypes and mutations in asymptomatic carriers].
- 1 July 2004
- p. 236-40
[Mutation of HCV-RNA and determination of its genome by RT-PCR].
- 1 July 2004
- p. 335-8
[Hepatitis C virus infection as a sexually transmitted disease].
- 6 May 2003
- Published by Wiley in Journal of Medical Virology
- Vol. 70 (3) , 350-354
Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: A prospective study
The factors contributing to the prognosis of hepatitis B virus (HBV)‐ related chronic liver disease were assessed prospectively in 72 patients with chronic hepatitis B confirmed clinically and pathologically. A comparative study was undertaken between patients infected with genotype B and those with genotype C. During the follow‐up period, 13 (81.3%) of 16 patients with genotype B who were initially hepatitis B e antigen (HBeAg) positive became HBeAg negative and 14 (51.9%) of 27 with genotype C became HBeAg negative. HBeAg had been cleared in 8 (61.5%) of 13 patients with genotype B within the first 2 years of the follow‐up, but in only one (7.1%) of 14 with genotype C (P < 0.05). Four (11.4%) of 35 patients with genotype B had progressed to cirrhosis, whereas, 12 (32.4%) of 37 patients with genotype C progressed to cirrhosis, including two patients with hepatocellular carcinoma. Multivariate analysis showed that difference in HBV genotype influenced significantly either the clearance of HBeAg or the development of cirrhosis. In conclusion, HBeAg was cleared from sera more frequently and earlier in patients with genotype B compared with those with genotype C, and development of cirrhosis occurred less frequently in patients with genotype B compared with those with genotype C. Thus, HBV genotypes may influence the prognosis of HBV‐related chronic liver disease. J. Med. Virol. 70:350–354, 2003.
- 6 May 2003
- Published by Wiley in Journal of Medical Virology
- Vol. 70 (3) , 350-354
Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: A prospective study
The factors contributing to the prognosis of hepatitis B virus (HBV)‐ related chronic liver disease were assessed prospectively in 72 patients with chronic hepatitis B confirmed clinically and pathologically. A comparative study was undertaken between patients infected with genotype B and those with genotype C. During the follow‐up period, 13 (81.3%) of 16 patients with genotype B who were initially hepatitis B e antigen (HBeAg) positive became HBeAg negative and 14 (51.9%) of 27 with genotype C became HBeAg negative. HBeAg had been cleared in 8 (61.5%) of 13 patients with genotype B within the first 2 years of the follow‐up, but in only one (7.1%) of 14 with genotype C (P < 0.05). Four (11.4%) of 35 patients with genotype B had progressed to cirrhosis, whereas, 12 (32.4%) of 37 patients with genotype C progressed to cirrhosis, including two patients with hepatocellular carcinoma. Multivariate analysis showed that difference in HBV genotype influenced significantly either the clearance of HBeAg or the development of cirrhosis. In conclusion, HBeAg was cleared from sera more frequently and earlier in patients with genotype B compared with those with genotype C, and development of cirrhosis occurred less frequently in patients with genotype B compared with those with genotype C. Thus, HBV genotypes may influence the prognosis of HBV‐related chronic liver disease. J. Med. Virol. 70:350–354, 2003.
- 2 July 2002
- Published by Wiley in Journal of Medical Virology
- Vol. 67 (4) , 484-489
Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan
The present study was designed to examine the distribution of hepatitis B virus (HBV) genotypes among patients at various stages of chronic liver disease type B in Okinawa Prefecture, Japan, where the prevalence of hepatitis B surface antigen is the highest in Japan despite the lowest mortality rate from primary liver cancer. Serum samples from 227 HBV carriers were determined for HBV genotype by polymerase chain reaction (PCR)-restriction fragment length polymorphism. Five of 227 sera were negative for HBV DNA by nested PCR and were excluded from the genotype analysis. Genotype B was predominant in asymptomatic carriers (45/67, 67%), whereas genotype C was predominant in chronic liver disease: 49% (50/103) in patients with chronic hepatitis, 63% (20/32) in patients with cirrhosis, and 60% (12/20) in patients with hepatocellular carcinoma. The distribution of genotype B decreased with increasing liver disease severity. However, this tendency was seen among patients aged less than 50 years old, whereas the prevalence of genotype B was similar among carriers with various liver diseases who were older than age 50. In conclusion, HBV genotype B was prevalent and less frequent among patients with advanced liver disease, particularly in patients aged less than 50 years. These findings suggest that the preponderance of genotype B is responsible for the low mortality rate of primary liver cancer associated with HBV seen in Okinawa Prefecture, despite having the highest HBV carrier rate in Japanese. J. Med. Virol. 67:484–489, 2002.
- 2 July 2002
- Published by Wiley in Journal of Medical Virology
- Vol. 67 (4) , 484-489
Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan
The present study was designed to examine the distribution of hepatitis B virus (HBV) genotypes among patients at various stages of chronic liver disease type B in Okinawa Prefecture, Japan, where the prevalence of hepatitis B surface antigen is the highest in Japan despite the lowest mortality rate from primary liver cancer. Serum samples from 227 HBV carriers were determined for HBV genotype by polymerase chain reaction (PCR)-restriction fragment length polymorphism. Five of 227 sera were negative for HBV DNA by nested PCR and were excluded from the genotype analysis. Genotype B was predominant in asymptomatic carriers (45/67, 67%), whereas genotype C was predominant in chronic liver disease: 49% (50/103) in patients with chronic hepatitis, 63% (20/32) in patients with cirrhosis, and 60% (12/20) in patients with hepatocellular carcinoma. The distribution of genotype B decreased with increasing liver disease severity. However, this tendency was seen among patients aged less than 50 years old, whereas the prevalence of genotype B was similar among carriers with various liver diseases who were older than age 50. In conclusion, HBV genotype B was prevalent and less frequent among patients with advanced liver disease, particularly in patients aged less than 50 years. These findings suggest that the preponderance of genotype B is responsible for the low mortality rate of primary liver cancer associated with HBV seen in Okinawa Prefecture, despite having the highest HBV carrier rate in Japanese. J. Med. Virol. 67:484–489, 2002.